Diagnos (TSE:ADK) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Diagnos Inc., a Canadian AI tech firm specializing in early health issue detection, announced the granting of 1,550,000 stock options to its directors and officers. These options will vest over two years, starting from their grant date on October 3, 2024, and have an exercise price of $0.37 per common share with an expiry on October 3, 2029.
For further insights into TSE:ADK stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue